Zynerba rises on positive data from genetic disorder trial

Zynerba Pharmaceuticals

22/06/2022 12:17

** Shares of drug developer Zynerba Pharmaceuticals  ZYNE.O 
rise 6.3% to $1.17 premarket
    ** Co, on Tuesday after market, reported positive data from
mid-stage study testing Zygel as treatment of behavioral
symptoms in children and adolescents with 22q11.2 deletion
syndrome  urn:newsml:reuters.com:*:nGNX1WkX8t
    ** 22q11.2 deletion syndrome is a genetic disorder caused by
a defect in chromosome 22
    ** Based on results, ZYNE will request a meeting with the
U.S. FDA to discuss data and the regulatory path forward
    ** As of last close, stock was down ~61.8% YTD 

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))